Drug Trial Radar · NCT07144163
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Dec 11, 2025
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Crinetics Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.
Conditions
- Congenital Adrenal Hyperplasia
- Classic Congenital Adrenal Hyperplasia
Interventions
AtumelnantDrug
Atumelnant, tablets, once daily by mouth
PlaceboDrug
Placebo, tablets, once daily by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with morning post-GC A4 ≤ ULN who are on physiologic GC replacement.Time frame: Week 32
Locations
82 sites in 15 countries. Site status is shown where the registry gives one.
Crinetics Study Site
Los Angeles, California · Recruiting
Crinetics Study Site
Aurora, Colorado · Recruiting
Crinetics Study Site
Gainesville, Florida · Recruiting
Crinetics Study Site
Atlanta, Georgia · Recruiting
Crinetics Study Site
Chicago, Illinois · Recruiting
Crinetics Study Site
Baltimore, Maryland · Recruiting
Crinetics Study Site
Ann Arbor, Michigan · Recruiting
Crinetics Study Site
Minneapolis, Minnesota · Recruiting
Crinetics Study Site
Rochester, Minnesota · Recruiting
Crinetics Study Site
New Brunswick, New Jersey · Recruiting
Crinetics Study Site
Philadelphia, Pennsylvania · Recruiting
Crinetics Study Site
Pittsburgh, Pennsylvania · Recruiting
Crinetics Study Site
Dallas, Texas · Recruiting
Crinetics Study Site
Charlottesville, Virginia · Recruiting
Crinetics Study Site
Milwaukee, Wisconsin · Recruiting
Crinetics Study Site
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Crinetics Study Site
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Crinetics Study Site
CABA, Buenos Aires F.D., Argentina · Recruiting
Crinetics Study Site
CABA, Buenos Aires F.D., Argentina · Recruiting
Crinetics Study Site
Córdoba, Córdoba Province, Argentina · Recruiting
Crinetics Study Site
Herston, Queensland, Australia · Recruiting
Crinetics Study Site
Woolloongabba, Queensland, Australia · Recruiting
Crinetics Study Site
Adelaide, South Australia, Australia · Recruiting
Crinetics Study Site
Parkville, Victoria, Australia · Recruiting
Crinetics Study Site
Nedlands, Western Australia, Australia · Recruiting
Crinetics Study Site
Vienna, Austria · Recruiting
Crinetics Study Site
Graz, Styria, Austria · Recruiting
Crinetics Study Site
Fortaleza, Ceará, Brazil · Recruiting
Crinetics Study Site
Brasília, Federal District, Brazil · Recruiting
Crinetics Study Site
Belo Horizonte, Minas Gerais, Brazil · Recruiting
Crinetics Study Site
Curitiba, Paraná, Brazil · Recruiting
Crinetics Study Site
Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting
Crinetics Study Site
Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting
Crinetics Study Site
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Crinetics Study Site
Botucatu, São Paulo, Brazil · Recruiting
Crinetics Study Site
Campinas, São Paulo, Brazil · Recruiting
Crinetics Study Site
Ribeirão Preto, São Paulo, Brazil · Recruiting
Crinetics Study Site
São Paulo, São Paulo, Brazil · Recruiting
Crinetics Study Site
São Paulo, São Paulo, Brazil · Recruiting
Crinetics Study Site
Halifax, Nova Scotia, Canada · Recruiting
Showing 40 of 82 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.